The following tracks showcase the areas of focus for this year’s Biomedical HIV Prevention Summit. We encourage abstract submissions that speak from an intersectional lens and that are inclusive of individuals from diverse backgrounds, including, but not limited to, people of color, individuals of trans experience, MSM, and people who inject drugs. We also look forward to engaging content that facilitates learning in virtual spaces.
We must develop and test finance and access models to increase the uptake of PrEP among those with less or no resources to access it. It is essential to understand that one model will not address the needs of all the groups that might benefit from PrEP. For that reason, we look forward to including workshops from diverse perspectives and populations focusing on the gender, race, and sexuality spectrum. Examples of these models are drug and co-pays financing programs, clinical care, monitoring, adherence support, and initiatives that address social determinants and health disparities. These workshops will also engage attendees in the conversation about funding for community and clinical institutions around models proven to be effective in the implementation of biomedical prevention efforts. Overall, this track looks at the implementation and evaluation of finance and access models and how they impact community uptake.
Ending the HIV Epidemic (EHE) is the federal plan to end the HIV epidemic in the United States by 2025. Such an initiative will require national-level coordination across federal agencies, community organizations, clinical providers, health departments, and other key stakeholders. Biomedical prevention, including PrEP, TasP, and PEP, will be critical to lowering the rates of infections to 90%. On this track, we will discuss the challenges and opportunities as the targeted jurisdictions develop their local plans, and the federal government roll out their own initiatives like “Ready, Set, PrEP”. Workshops will focus on the essential role of biomedical HIV prevention in ending the HIV epidemic. Track content will include a focus on populations affected disproportionately including, but not limited to, people of color, MSM, and individuals of trans experience.
Training programs and educational models must include the spectrum of stakeholders involved in ensuring biomedical HIV prevention is understood and accessed by the populations in need. All parts involved require education; from those looking for PrEP or viral suppression, to the community-based care and service providers, health clinic employees, doctors, and nurses. Education modalities might include peer-education, curriculum development, capacity building, collaborative learning, medical education, and online professional programs. This track will explore evidence-based training and educational models that are culturally competent and available to all stakeholders involved in biomedical HIV prevention, including finance, psychosocial services, and clinical care.
El acceso de las comunidades hispanoparlantes a estrategias biomédicas para prevenir el VIH, depende del acceso que estas poseen a la información y al cuidado médico. Es por esto que hemos diseñado esta área temática en español. Aquí se discutirán avances en las modalidades de PrEP, PEP y tratamiento como prevención (“TasP”, por sus siglas en inglés), a la vez que se incluirán las barreras encontradas al implementar programas durante COVID-19, el rol de la movilización comunitaria y el efecto desproporcional de la epidemia en estas comunidades. Además, se apunta a profundizar sobre los efectos del racismo, el estatus migratorio y las inequidades en el acceso a la prevención biomédica, incluyendo, pero no limitado a, HSH, personas de experiencia trans y aquellas que utilizan drogas intravenosas.
In order to be successful in the implementation of biomedical HIV prevention, it is essential to mobilize the communities most impacted by HIV. Community mobilization is critical in putting the interests of its members to the fronts. Whether it is through protest, demanding representation in clinical trials, or lobbying for fair policies, community mobilization has proven to be effective in promoting change. We should not underestimate the power of community and how it affects health outcomes. Engaged communities add a layer of care and trust not always achieved by mainstream health care. Also, reaching increased health literacy around biomedical HIV prevention, is only effective when peer and community support is available. Also, mobilizing communities statistically overrepresented including, but not limited to, people of color, MSM, individuals of trans experience is essential for their self-empowerment and mobilization.
We are at a historic juncture. We not only continue fighting to end the HIV epidemic, but also of COVID-19. Our experience with HIV, and the management of the COVID-19 pandemic, reminds us that ignoring or denying such public health threats puts disadvantaged populations in an even worst position. It is not about prioritizing one over the other, but about identifying how in-place health systems serve to continue HIV prevention while addressing the crisis caused by COVID-19. Therefore, this track seeks to identify the barriers and opportunities to continue providing prevention services during the pandemic. Presenters will discuss how organizations have adapted to continue offering services while showing qualitative and quantitative data on the populations that have been disproportionately affected by COVID-19 and HIV, including, but not limited to, people of color, individuals of trans experience, MSM and people who inject drugs. It will also inform how health systems developed around HIV could facilitate COVID-19 testing and its long-awaited treatment and vaccination.
There is little clinical information about the use of current biomedical HIV prevention methods on cisgender women. However, according to the CDC, cisgender women comprise 19% of the new cases reported in the United States for 2018. This track seeks to center the discussion around qualitative and quantitative data on cisgender women and biomedical HIV prevention. The track will also discuss the barriers and facilitators for implementing programs and access to biomedical HIV prevention modalities.
Data has continually shown that HIV does not affect all populations equally. Instead, a more impactful effect is observed on those who lack access to medical treatment and quality care. That is why, for example, the limited uptake and access to PrEP among Black and Latino gay men, compared to white gay men, is a matter of health disparities and social justice. On this track, we will deepen into the barriers and facilitators that affect awareness and uptake on these and other populations including, but not limited to, people of color, individuals of trans experience, and people who inject drugs. The discussion will also focus on how the social determinants of health impact access to biomedical HIV prevention and medical monitoring, PrEP stigma, and cultural values around sexuality.
This track will discuss current approaches to implementation science and evaluation related to biomedical HIV prevention and how they inform interventions to increase PrEP awareness and uptake.
There is no doubt that PrEP is an effective method to prevent HIV transmission. But, for it to be impactful, it must successfully follow the PrEP continuum of care that builds upon awareness and uptake to adherence and retention. This track seeks to shed light on how to overcome the challenges that prevent the sustainability of a PrEP continuum of care while identifying facilitators that might be replicated elsewhere.